Association of DNA repair and steroid metabolism gene polymorphisms with clinical late toxicity in patients treated with conformal radiotherapy for prostate cancer

Clinical Cancer Research

Volumn 12, Issue 8, 2006, Pages 2545-2554

  Damaraju, Sambasivarao ^a,b,c   Murray, David ^a,c   Dufour, Jennifer ^b   Carandang, Diana ^b   Myrehaug, Sten ^a,c   Fallone, Gino ^a,c   Field, Colin ^a,b   Greiner, Russell ^b,c   Hanson, John ^a   Cass, Carol E ^a,b,c   Parliament, Matthew ^a,c  

^a CROSS CANCER INSTITUTE   (Canada)

^b Alberta Cancer Board   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE DEPENDENT DNA LIGASE; ALDOSTERONE SYNTHASE; ATM PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CYTOCHROME P450 17; CYTOCHROME P450 17A1; CYTOCHROME P450 1A1; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A5; ESTERASE; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR 1; GLUCOCORTICOID RECEPTOR; NIBRIN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; PROTEIN BCL 2; PROTEIN MSH6; RAD51 PROTEIN; RAD52 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

5' UNTRANSLATED REGION; ADULT; AGED; APOPTOSIS; ARTICLE; BLADDER DISEASE; BLOOD SAMPLING; CELL COMMUNICATION; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED STUDY; DNA REPAIR; FOLLOW UP; GENETIC SUSCEPTIBILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIATION INJURY; RECTUM DISEASE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; STEROID METABOLISM;

AGED; BRCA1 PROTEIN; BRCA2 PROTEIN; COHORT STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DNA LIGASES; DNA REPAIR; DNA-BINDING PROTEINS; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RECTUM; RETROSPECTIVE STUDIES; STEROIDS; URINARY BLADDER; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 33646411483     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2703     Document Type: Article

References (62)

1. Zelefsky MJ, Fuks Z, Hunt M, et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 2001;166:876-81.
2. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002;53:1097-105.
3. Ryu JK, Winter K, Michalski JM, et al. Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy). Int J Radiat Oncol Biol Phys 2002;54:1036-46.
4. Koper PC, Jansen P, van Putten W, et al. Gastrointestinal and genito-urinary morbidity after 3D conformal radiotherapy of prostate cancer: observations of a randomized trial. Radiother Oncol 2004;73:1-9.
5. Chism DB, Horwitz EM, Hanlon AL, Pinover WH, Mitra RK, Hanks GE. Late morbidity profiles in prostate cancer patients treated to 79-84 Gy by a simple four-field coplanar beam arrangement. Int J Radiat Oncol Biol Phys 2003;55:71-7.
6. Tucker SL, Cheung R, Dong L, et al. Dose-volume response analyses of late rectal bleeding after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2004;59:353-65.
7. Skwarchuk MW, Jackson A, Zelefsky MJ, et al. Late rectal toxicity after conformal radiotherapy of prostate cancer (I): multivariate analysis and dose-response. Int J Radiat Oncol Biol Phys 2000;47:103-13.
8. Russell NS, Grummels A, Hart AA, et al. Low predictive value of intrinsic fibroblast radiosensitivity for fibrosis development following radiotherapy for breast cancer. Int J Radiat Biol 1998;73:661-70.
9. Angele S, Romestaing P, Moullan N, et al. ATM haplotypes and cellular response to DNA damage: association with breast cancer risk and clinical radiosensitivity. Cancer Res 2003;63:8717-25.
10. Andreassen CN, Alsner J, Overgaard J. Does variability in normal tissue reactions after radiotherapy have a genetic basis-where and how to look for it? Radiother Oncol 2002;64:131-40.
11. Quarmby S, Fakhoury H, Levine E, et al. Association of transforming growth factor beta-1 single nucleotide polymorphisms with radiation-induced damage to normal tissues in breast cancer patients. Int J Radiat Biol 2003;79:137-43.
12. Severin DM, Leong T, Cassidy B, et al. Novel DNA sequence variants in the hHR21 DNA repair gene in radiosensitive cancer patients. Int J Radiat Oncol Biol Phys 2001;50:1323-31.
13. Varghese S, Schmidt-Ullrich RK, Dritschilo A, Jung M. Enhanced radiation late effects and cellular radiation sensitivity in an ATM heterozygous breast cancer patient. Radiat Oncol Investig 1999;7:231-7.
14. Andreassen CN, Alsner J, Overgaard M, Overgaard J. Prediction of normal tissue radiosensitivity from polymorphisms in candidate genes. Radiother Oncol 2003;69:127-35.
15. Andreassen CN, Sorensen FB, Overgaard J, Alsner J. Optimisation and validation of methods to assess single nucleotide polymorphisms (SNPs) in archival histological material. Radiother Oncol 2004;72:351-6.
16. Price EA, Bourne SL, Radbourne R, et al. Rare microsatellite polymorphisms in the DNA repair genes XRCC1, XRCC3 and XRCC5 associated with cancer in patients of varying radiosensitivity. Somat Cell Mol Genet 1997;23:237-47.
17. Leadon SA. Repair of DNA damage produced by ionizing radiation: a minireview. Semin Radiat Oncol 1996;6:295-305.
18. Haimovitz-Friedman A. Radiation-induced signal transduction and stress response. Radiat Res 1998;150:5102-8.
19. Wood RD, Mitchell M, Sgouros J, Lindahl T. Human DNA repair genes. Science 2001;291:1284-9.
20. Mohrenweiser HW, Xi T, Vazquez-Matias J, Jones IM. Identification of 127 amino acid substitution variants in screening 37 DNA repair genes in humans. Cancer Epidemiol Biomarkers Prev 2002;11:1054-64.
21. Ting JY, Wu X, Fiedler JA, Yang C, Watzich ML, Markoe A. Dose-volume histograms for bladder and rectum. Int J Radiat Oncol Biol Phys 1997;38:1105-11.
22. Stavrev PV, Hristov DH, Seuntjens JP. On the consistent use of organ definitions and radiobiological models for the evaluation of complication probabilities of "tubular" organs. Int J Radiat Oncol Biol Phys 2002;52:1150-2.
23. Rosen EM, Fan S, Goldberg ID, Rockwell S. Biological basis of radiation sensitivity. Part 1: factors governing radiation tolerance. Oncology (Williston Park) 2000;14:543-50.
24. Rosen EM, Fan S, Rockwell S, Goldberg ID. The molecular and cellular basis of radiosensitivity: implications for understanding how normal tissues and tumors respond to therapeutic radiation. Cancer Invest 1999;17:56-72.
25. Chang-Claude J, Popanda O, Tan XL, et al. Association between polymorphisms in the DNA repair genes, XRCC1, APE1, and XPD and acute side effects of radiotherapy in breast cancer patients. Clin Cancer Res 2005;11:4802-9.
26. Fernet M, Hall J. Genetic biomarkers of therapeutic radiation sensitivity. DNA Repair (Amst) 2004;3:1237-43.
27. Stone HB, Coleman CN, Anscher MS, McBride WH. Effects of radiation on normal tissue: consequences and mechanisms. Lancet Oncol 2003;4:529-36.
28. Kuschel B, Auranen A, McBride S, et al. Variants in DNA double-strand break repair genes and breast cancer susceptibility. Hum Mol Genet 2002;11:1399-407.
29. Morgan ET. Regulation of cytochrome p450 by inflammatory mediators: why and how? Drug Metab Dispos 2001;29:207-12.
30. Chang BL, Zheng SL, Isaacs SD, et al. Polymorphisms in the CYP1A1 gene are associated with prostate cancer risk. Int J Cancer 2003;106:375-8.
31. Chang BL, Zheng SL, Isaacs SD, et al. Polymorphisms in the CYP1B1 gene are associated with increased risk of prostate cancer. Br J Cancer 2003;89:1524-9.
32. Finnstrom N, Bjelfman C, Soderstrom TG, et al. Detection of cytochrome P450 mRNA transcripts in prostate samples by RT-PCR. Eur J Clin Invest 2001;31:880-6.
33. Fukatsu T, Hirokawa Y, Araki T, et al. Genetic polymorphisms of hormone-related genes and prostate cancer risk in the Japanese population. Anticancer Res 2004;24:2431-7.
34. Tanaka Y, Sasaki M, Kaneuchi M, Shiina H, Igawa M, Dahiya R. Polymorphisms of estrogen receptor alpha in prostate cancer. Mol Carcinog 2003;37:202-8.
35. Wadelius M, Andersson AO, Johansson JE, Wadelius C, Rane E. Prostate cancer associated with CYP17 genotype. Pharmacogenetics 1999;9:635-9.
36. Johnson MM, Houck J, Chen C. Screening for deleterious nonsynonymous single-nucleotide polymorphisms in genes involved in steroid hormone metabolism and response. Cancer Epidemiol Biomarkers Prev 2005;14:1326-9.
37. Vittinghoff E, Glidden DV, Shiboski SC, McCulloch CE. Regression methods in biostatistics: New York (NY): Springer Science + Business Media Inc.; 2005.
38. Jackson A, Skwarchuk MW, Zelefsky MJ, et al. Late rectal bleeding after conformal radiotherapy of prostate cancer. II. Volume effects and dose-volume histograms. Int J Radiat Oncol Biol Phys 2001;49:685-98.
39. Cejka P, Stojic L, Marra G, Jiricny J. Is mismatch repair really required for ionizing radiation-induced DNA damage signaling? Nat Genet 2004;36:432-3; author reply 4.
40. Allen C, Halbrook J, Nickoloff JA. Interactive competition between homologous recombination and non-homologous end joining. Mol Cancer Res 2003;1:913-20.
41. Takata M, Sasaki MS, Sonoda E, et al. Homologous recombination and non-homologous end-joining pathways of DNA double-strand break repair have overlapping roles in the maintenance of chromosomal integrity in vertebrate cells. EMBO J 1998;17:5497-508.
42. Listgarten J, Damaraju S, Poulin B, et al. Predictive models for breast cancer susceptibility from multiple single nucleotide polymorphisms. Clin Cancer Res 2004;10:2725-37.
43. Qiao Y, Spitz MR, Shen H, et al. Modulation of repair of ultraviolet damage in the host-cell reactivation assay by polymorphic XPC and XPD/ERCC2 genotypes. Carcinogenesis 2002;23:295-9.
44. King CR, Yu J, Freimuth RR, McLeod HL, Marsh S. Interethnic variability of ERCC2 polymorphisms. Pharmacogenomics J 2005;5:54-9.
45. Girard PM, Kysela B, Harer CJ, Doherty AJ, Jeggo PA. Analysis of DNA ligase IV mutations found in LIG4 syndrome patients: the impact of two linked polymorphisms. Hum Mol Genet 2004;13:2369-76.
46. Riballo E, Doherty AJ, Dai Y, et al. Cellular and biochemical impact of a mutation in DNA ligase IV conferring clinical radiosensitivity. J Biol Chem 2001;276: 31124-32.
47. Riballo E, Critchlow SE, Teo SH, et al. Identification of a defect in DNA ligase IV in a radiosensitive leukaemia patient. Curr Biol 1999;9:699-702.
48. Cesaretti JA, Stock RG, Lehrer S, et al. ATM sequence variants are predictive of adverse radiotherapy response among patients treated for prostate cancer. Int J Radiat Oncol Biol Phys 2005;61:196-202.
49. Wojnowski L, Hustert E, Klein K, et al. Re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 2002;94:630-1; author reply 1-2.
50. Brown MA, Edwards S, Hoyle E, et al. Polymorphisms of the CYP2D6 gene increase susceptibility to ankylosing spondylitis. Hum Mol Genet 2000;9:1563-6.
51. Romkes-Sparks M, Mnuskin A, Chern HD, et al. Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity. Carcinogenesis 1994;15:1955-61.
52. Febbo PG, Kantoff PW, Giovannucci E, et al. Debrisoquine hydroxylase (CYP2D6) and prostate cancer. Cancer Epidemiol Biomarkers Prev 1998;7:1075-8.
53. Collins JE, Goward ME, Cole CG, et al. Reevaluating human gene annotation: a second-generation analysis of chromosome 22. Genome Res 2003;13:27-36.
54. Li WQ, Qureshi HY, Liacini A, Dehnade F, Zafarullah M. Transforming growth factor Beta1 induction of tissue inhibitor of metalloproteinases 3 in articular chondrocytes is mediated by reactive oxygen species. Free Radic Biol Med 2004;37:196-207.
55. Qi JH, Ebrahem Q, Moore N, et al. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med 2003;9:407-15.
56. Tunuguntla R, Ripley D, Sang QX, Chegini N. Expression of matrix metalloproteinase-26 and tissue inhibitors of metalloproteinases TIMP-3 and -4 in benign endometrium and endometrial cancer. Gynecol Oncol 2003;89:453-9.
57. Healey CS, Dunning AM, Teare MD, et al. A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability. Nat Genet 2000;26:362-4.
58. Awad MR, El-Gamel A, Hasleton P, Turner DM, Sinnott PJ, Hutchinson IV. Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation 1998;66:1014-20.
59. Kupelian PA, Thakkar VV, Khuntia D, Reddy CA, Klein EA, Mahadevan A. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes. Int J Radiat Oncol Biol Phys 2005;63:1463-8.
60. Nichol A, Chung P, Lockwood G, et al. A phase II study of localized prostate cancer treated to 75.6 Gy with 3D conformal radiotherapy. Radiother Oncol 2005;76:11-7.
61. Michalski JM, Winter K, Purdy JA, et al. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose level V. Int J Radiat Oncol Biol Phys 2005;62:706-13.
62. Liu M, Pickles T, Agranovich A, et al. Impact of neoadjuvant androgen ablation and other factors on late toxicity after external beam prostate radiotherapy. Int J Radiat Oncol Biol Phys 2004;58:59-67.